• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: KANEKA CORPORATION LIPOSORBER LA-15 SYSTEM; LIPOPROTEIN, LOW DENSITY, REMOVAL

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

KANEKA CORPORATION LIPOSORBER LA-15 SYSTEM; LIPOPROTEIN, LOW DENSITY, REMOVAL Back to Search Results
Model Number LA-15
Medical Device Problem Code Adverse Event Without Identified Device or Use Problem (2993)
Health Effect - Clinical Codes Low Blood Pressure/ Hypotension (1914); Loss of consciousness (2418)
Date of Event 02/17/2020
Type of Reportable Event Serious Injury
Additional Manufacturer Narrative
During temporary withdrawal from la-15 treatment for toilet the blood pressure was further reduced and the consciousness was lost due to a decrease in blood circulation in the body, and due to a rise in blood bradykinin caused by gradual increase in plasma flow during the course of treatment.There was a slight decrease in blood pressure, nausea, and a feeling of fainting in the first treatment, however the treatment could have finished until the target plasma treatment volume.The loss of consciousness occurred in the second treatment also possibly due to the bad patient's physical condition on the day of the second treatment.
 
Event or Problem Description
The case is a patient with familial hypercholesterolemia and hyper-lp (a)emia.During the second la-15 treatment the patient temporarily broke away from la-15 treatment due to toilet, and the blood pressure decreased (98 / 56mmhg) and the patient lost consciousness.The blood pressure recovered to 124/68 and thereafter la-15 treatment was resumed.La-15 treatment was discontinued at a plasma treatment volume of 3.8 l although the target volume was set to 4.45l.The first la-15 treatment was conducted two weeks before the second treatment.Although mild decrease in the blood pressure to 90's, feeling of faint and nausea during the treatment were observed.The target plasma treatment volume 4.4l was accomplished.Concomitant medications: lisinopril (ace-inhibitor) was withdrew 6 days before the first la-15 treatment.Plavix (antiplatelet drug) zetia (cholesterol lowering drug).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
LIPOSORBER LA-15 SYSTEM
Common Device Name
LIPOPROTEIN, LOW DENSITY, REMOVAL
Manufacturer (Section D)
KANEKA CORPORATION
2-3-18,
nakanoshima, kita-ku,
osaka, 530-8 288
JA  530-8288
MDR Report Key9838946
Report Number3002808904-2020-00005
Device Sequence Number742732
Product Code MMY
UDI-Device Identifier14993478010110
UDI-Public14993478010110
Combination Product (Y/N)N
Initial Reporter StateUT
Initial Reporter CountryUS
PMA/510(K) Number
P910018
Number of Events Summarized1
Summary Report (Y/N)N
Reporter Type Manufacturer
Report Source health professional
Initial Reporter Occupation Other
Type of Report Initial
Report Date (Section B) 02/21/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Operator of Device Health Professional
Device Model NumberLA-15
Device Catalogue NumberN/A
Was Device Available for Evaluation? No
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 02/21/2020
Initial Report FDA Received Date03/17/2020
Patient Sequence Number1
Outcome Attributed to Adverse Event Other;
Patient Age42 YR
Patient Weight86
-
-